CalciMedica’s (CALC) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of CalciMedica (NASDAQ:CALC) in a report released on Thursday morning,Benzinga reports. HC Wainwright currently has a $16.00 price objective on the stock.

CalciMedica Trading Down 1.2 %

NASDAQ:CALC opened at $3.33 on Thursday. CalciMedica has a 12-month low of $2.68 and a 12-month high of $8.38. The firm has a market cap of $44.89 million, a price-to-earnings ratio of -3.08 and a beta of 1.30. The company’s 50-day moving average is $4.04 and its two-hundred day moving average is $4.52.

Insiders Place Their Bets

In related news, Director Fred A. Middleton purchased 87,744 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was purchased at an average price of $3.75 per share, with a total value of $329,040.00. Following the completion of the transaction, the director now owns 814,300 shares of the company’s stock, valued at approximately $3,053,625. This trade represents a 12.08 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert N. Wilson purchased 54,000 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were bought at an average cost of $3.72 per share, for a total transaction of $200,880.00. Following the purchase, the director now owns 364,196 shares of the company’s stock, valued at $1,354,809.12. This trade represents a 17.41 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders bought 312,944 shares of company stock valued at $1,172,910. Company insiders own 41.55% of the company’s stock.

Hedge Funds Weigh In On CalciMedica

A hedge fund recently raised its stake in CalciMedica stock. Geode Capital Management LLC boosted its stake in CalciMedica, Inc. (NASDAQ:CALC) by 51.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 66,553 shares of the company’s stock after purchasing an additional 22,525 shares during the period. Geode Capital Management LLC owned approximately 0.62% of CalciMedica worth $295,000 at the end of the most recent reporting period.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.